Dobrovolskaya Darya, Asaturova Aleksandra, Badlaeva Alina, Tregubova Anna, Mogirevskaya Olga, Dzharullaeva Zaira, Davydova Yulia, Palicelli Andrea, Bayramova Guldana, Sukhikh Gennady
FSBI "National Medical Research Centre for Obstetrics, Gynecology and Perinatology Named After Academician V.I. Kulakov", Ministry of Health of the Russian Federation, 4, Oparina Street, 117513 Moscow, Russia.
Hospital Named After S.P. Botkin, Botkin Hospital, 125284 Moscow, Russia.
J Clin Med. 2025 May 12;14(10):3376. doi: 10.3390/jcm14103376.
Human papillomavirus (HPV) infection is a major risk factor for cervical cancer, demanding improved diagnostic strategies to distinguish between transient infections and those requiring intervention. : This systematic review and meta-analysis evaluated the diagnostic accuracy of HPV L1 immunocytochemistry (ICC) in detecting high-grade cervical intraepithelial neoplasia (CIN2+). : We systematically analyzed data from 15 studies (PROSPERO 2022 CRD42022375916) comprising 3804 cervical smears with varying cytological findings (NILM to ≥ASC-US). : The pooled sensitivity for detecting CIN2+ was 80.7% (95% CI: 76.2-84.4%); however, substantial heterogeneity was present (I = 65.97%, < 0.001). Similarly, the pooled specificity was 56.9% (95% CI: 49.6-64%), with even higher heterogeneity (I = 90.46%, < 0.001). This considerable heterogeneity, which may be attributable to methodological variations or regional differences in HPV prevalence and genotyping, limits the generalizability of these findings. Furthermore, the moderate specificity suggests a high rate of false positives, limiting the clinical utility of HPV L1 ICC as a standalone diagnostic test. : In conclusion, although HPV L1 ICC exhibits acceptable sensitivity for detecting CIN2+, its limitations, including low specificity and substantial heterogeneity, necessitate its use as an adjunct to other established diagnostic methods, alongside further research to enhance its diagnostic performance, and necessitate its use as a supplementary test alongside established diagnostic methods, pending further research to refine its clinical utility.
人乳头瘤病毒(HPV)感染是宫颈癌的主要危险因素,因此需要改进诊断策略,以区分一过性感染和需要干预的感染。本系统评价和荟萃分析评估了HPV L1免疫细胞化学(ICC)检测高级别宫颈上皮内瘤变(CIN2+)的诊断准确性。我们系统分析了15项研究(PROSPERO 2022 CRD42022375916)的数据,这些研究包括3804份具有不同细胞学结果(无上皮内病变或恶性病变至≥非典型鳞状细胞)的宫颈涂片。检测CIN2+的合并敏感度为80.7%(95%CI:76.2-84.4%);然而,存在显著异质性(I² = 65.97%,P < 0.001)。同样,合并特异度为56.9%(95%CI:49.6-64%),异质性更高(I² = 90.46%,P < 0.001)。这种相当大的异质性可能归因于方法学差异或HPV流行率及基因分型的地区差异,限制了这些结果的可推广性。此外,中等特异度表明假阳性率较高,限制了HPV L1 ICC作为独立诊断试验的临床应用价值。总之,尽管HPV L1 ICC在检测CIN2+方面表现出可接受的敏感度,但其局限性,包括低特异度和显著异质性,使其必须作为其他既定诊断方法的辅助手段使用,同时需要进一步研究以提高其诊断性能,并且在进一步研究完善其临床应用价值之前,必须与既定诊断方法一起作为补充试验使用。